Fortress Biotech (FBIO) Proxy Filing summary
Event summary combining transcript, slides, and related documents.
Proxy Filing summary
2 Dec, 2025Executive summary
Annual Meeting scheduled for June 17, 2025, will be held virtually to enhance shareholder access and participation.
Shareholders will vote on director elections, auditor ratification, executive compensation, frequency of say-on-pay, and amendments to the Certificate of Incorporation including officer exculpation.
Proxy materials are available online, with options for paper copies upon request; voting can be done online, by phone, mail, or during the meeting.
Voting matters and shareholder proposals
Election of seven directors for a one-year term.
Ratification of KPMG LLP as independent registered public accounting firm for 2025.
Advisory vote on executive compensation and on the frequency of such votes, with a recommendation for a three-year interval.
Approval of the Second Amended and Restated Certificate of Incorporation to provide for officer exculpation and other updates.
Other business may be transacted as appropriate.
Board of directors and corporate governance
Board consists of seven members, including the CEO and Executive Vice Chairman; five are independent under Nasdaq rules.
Board committees include Audit, Compensation, and Nominating and Corporate Governance, all with independent members.
Directors are expected to attend all meetings; in 2024, all attended at least 88% of meetings.
Stockholders can communicate with the Board via the General Counsel and Corporate Secretary.
Latest events from Fortress Biotech
- 600,000 shares registered for resale by Oaktree via warrants; no proceeds to the company.FBIO
Registration Filing18 Dec 2025 - 2.35 million shares registered for resale by stockholders; no proceeds to the company.FBIO
Registration Filing16 Dec 2025 - Annual meeting to vote on directors, auditor, executive pay, and officer exculpation.FBIO
Proxy Filing2 Dec 2025 - Virtual meeting to vote on directors, auditor, executive pay, and charter amendment.FBIO
Proxy Filing2 Dec 2025 - Registers 6.19M shares for resale from recent financings; no proceeds to the company.FBIO
Registration Filing29 Nov 2025 - All director and compensation proposals passed; officer exculpation amendment failed.FBIO
AGM 202525 Nov 2025 - Q3 2025 revenue up 21% to $17.6M, led by Emrosi's launch, strong growth, and asset sales.FBIO
Q3 202517 Nov 2025 - Q2 2025 net income surged to $13.4M, driven by the Checkpoint sale and Emrosi's strong launch.FBIO
Q2 202514 Aug 2025 - Emrosi FDA approval and late-stage pipeline progress offset revenue and cash declines.FBIO
Q3 202413 Jun 2025